Latest Tax Incentives News

Aeeris Ltd reported a profitable quarter with 13% revenue growth and launched its proprietary AWARE system, while navigating the departure of its founder and CEO.

Bellavista Resources confirms successful initial bioleaching tests at its Brumby deposit, recovering key critical minerals, while progressing due diligence on over 50 potential projects to expand its portfolio.

Infini Resources Limited has launched a C$10 million flow-through share offer to fund exploration at its Canadian uranium projects, aiming to advance drilling programs while navigating regulatory and market risks.

Pivotal Metals Limited has announced a C$2.6 million flow-through share offer targeting Canadian investors, aimed at funding critical minerals exploration in Quebec. The offer complements a concurrent institutional placement, underscoring the company’s aggressive growth strategy amid significant operational risks.

Zimi Limited reported a remarkable 367% increase in quarterly revenue alongside a successful $1.85 million capital raise and completion of its manufacturing relocation, setting the stage for accelerated growth in the smart home IoT sector.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

Aruma Resources has reported promising high-grade copper intersections from its maiden drilling at Fiery Creek, alongside new heavy mineral sands and gold-copper targets, supported by a $3.515 million placement to fund ongoing exploration.

Iondrive Limited has advanced its battery recycling ambitions by securing key partnerships in the US and Australia, commencing pilot plant construction, and gaining substantial government funding support.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

Microba Life Sciences reports a 145% jump in core microbiome test volumes and is on track to achieve regional break-even by FY26, supported by strategic cost cuts and a $14.5 million capital raise.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.